Urology Department, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain.
Pathology Department, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain.
Eur Urol Focus. 2021 Nov;7(6):1254-1259. doi: 10.1016/j.euf.2020.08.013. Epub 2020 Sep 8.
Diagnosis of prostate cancer is based on histopathological evaluation, which is time-consuming. Fluorescent confocal microscopy (FCM) is a novel technique that allows rapid tissue analysis.
To determine if FCM could be used for real-time diagnosis of prostate cancer and evaluate concordance with traditional analysis.
DESIGN, SETTING, AND PARTICIPANTS: From January 2019 to March 2020, 182 magnetic resonance imaging-targeted prostate biopsy cores from 57 consecutive biopsy-naïve men with suspected prostate cancer were taken. These were intraoperatively stained with acridine orange for analysis using FCM (VivaScope; MAVIG, Munich, Germany) and subsequently sent for traditional haematoxylin-eosin histopathological (HEH) examination. Two expert uropathologists analysed the FCM and HEH cores blinded to the counterpart results in a single institution.
Agreement between FCM and HEH analysis in terms of the presence of cancer was analysed at biopsy core and region of interest (ROI) levels, considering HEH as the reference test.
FCM allowed intraoperative assessment of prostate biopsy cores with strong histopathological evaluation agreement: Cohen's κ for agreement was 0.81 at the biopsy core level and 0.69 for the ROI level. Positive predictive values (85% and 83.78%) and negative predictive values (95.1% and 85.71%) were high at the biopsy core and ROI levels. These initial results are encouraging, but given the single-centre and preliminary nature of the study, further confirmation is required.
FCM allowed rapid evaluation of prostate biopsy cores. This technique is feasible and achieves rapid closure with a reliable diagnosis, parallel to the gold standard analysis. Initial results are promising but further studies are needed to validate and define the role of this technique.
A novel microscopic technique reduces the time needed to obtain a prostate cancer diagnosis by speeding up biopsy processing. Although the initial results are promising; this development needs to be confirmed in further studies.
前列腺癌的诊断基于组织病理学评估,这一过程耗时较长。荧光共焦显微镜(FCM)是一种新型技术,可实现快速的组织分析。
确定 FCM 是否可用于前列腺癌的实时诊断,并评估其与传统分析的一致性。
设计、地点和参与者:本研究于 2019 年 1 月至 2020 年 3 月期间,对 57 例疑似前列腺癌且初次接受前列腺活检的连续男性患者的 182 个磁共振成像靶向前列腺活检核心进行了研究。这些活检核心在术中用吖啶橙染色,然后使用 FCM(MAVIG,慕尼黑,德国)进行分析,随后进行传统的苏木精-伊红组织学(HEH)检查。在一家医疗机构中,两名泌尿科专家对 FCM 和 HEH 核心进行了分析,分析时对结果彼此不知情。
在活检核心和感兴趣区域(ROI)水平上,根据 HEH 作为参考测试,分析了 FCM 和 HEH 分析在癌症存在方面的一致性,考虑到 HEH 的一致性,kappa 系数为 0.81 和 0.69。活检核心和 ROI 水平的阳性预测值(85%和 83.78%)和阴性预测值(95.1%和 85.71%)较高。这些初步结果令人鼓舞,但鉴于本研究为单中心且初步性质,需要进一步确认。
FCM 可快速评估前列腺活检核心。该技术可行,可通过快速诊断实现快速闭合,与金标准分析相平行。初步结果很有前景,但需要进一步研究来验证和定义该技术的作用。
一种新型的显微镜技术通过加快活检处理速度,减少了获得前列腺癌诊断所需的时间。尽管初步结果令人鼓舞,但这一发展仍需要在进一步的研究中得到证实。